中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
18期
15-18
,共4页
药物疗法%舒必利%恶心%呕吐%托烷司琼
藥物療法%舒必利%噁心%嘔吐%託烷司瓊
약물요법%서필리%악심%구토%탁완사경
Drug therapy%Sulpiride%Nausea%Vomiting%Tropisetron
目的 探讨托烷司琼联合舒必利治疗顺铂方案化疗所致恶心、呕吐的疗效和安全性,进一步探讨对胃动素及胃泌素的影响.方法 将84例接受顺铂方案治疗并出现恶心、呕吐的患者按随机排列表法分为研究组(44例)和对照组(40例),两组患者都给予盐酸托烷司琼静脉推注,研究组同时口服舒必利.观察两种治疗方案的疗效、不良反应及对胃动素和胃泌素的影响.结果 研究组和对照组防治化疗所致的急性恶心的完全控制率分别为59.09％ (26/44)和37.50％ (15/40),有效率分别为90.91％(30/44)和72.50％ (29/40),差异均有统计学意义(P＜0.05);研究组和对照组防治化疗所致的急性呕吐的完全控制率分别为61.36％(27/44)和37.50％ (15/40),有效率分别为88.64％(39/44)和67.50％(27/40),差异均有统计学意义(P＜0.05);研究组和对照组防治化疗所致的延迟性恶心的完全控制率分别为54.54％ (24/44)和32.50％ (13/40),有效率分别为79.55％ (35/44)和57.50％ (23/40),差异均有统计学意义(P＜0.05);研究组和对照组防治化疗所致的延迟性呕吐的完全控制率分别为45.45％ (20/44)和22.50％ (9/40),有效率分别为75.00％(33/44)和52.50％(21/40),差异均有统计学意义(P＜0.05).研究组和对照组治疗后血浆胃动素较治疗前明显降低[(308.35±14.59) ng/L比(370.59±15.72) ng/L和(341.87±18.38) ng/L比(365.36±23.72) ng/L],血浆胃泌素较治疗前明显升高[(206.97±12.29) ng/L比(164.56±14.17) ng/L和(171.58±13.53) ng/L比(158.42±17.29)ng/L],差异有统计学意义(P＜0.05),且两组治疗后比较差异有统计学意义(P＜0.05).两组药物不良反应发生率比较差异无统计学意义(P＞0.05).结论 托烷司琼联合舒必利能比常规使用托烷司琼获得更好的止吐效果.
目的 探討託烷司瓊聯閤舒必利治療順鉑方案化療所緻噁心、嘔吐的療效和安全性,進一步探討對胃動素及胃泌素的影響.方法 將84例接受順鉑方案治療併齣現噁心、嘔吐的患者按隨機排列錶法分為研究組(44例)和對照組(40例),兩組患者都給予鹽痠託烷司瓊靜脈推註,研究組同時口服舒必利.觀察兩種治療方案的療效、不良反應及對胃動素和胃泌素的影響.結果 研究組和對照組防治化療所緻的急性噁心的完全控製率分彆為59.09％ (26/44)和37.50％ (15/40),有效率分彆為90.91％(30/44)和72.50％ (29/40),差異均有統計學意義(P＜0.05);研究組和對照組防治化療所緻的急性嘔吐的完全控製率分彆為61.36％(27/44)和37.50％ (15/40),有效率分彆為88.64％(39/44)和67.50％(27/40),差異均有統計學意義(P＜0.05);研究組和對照組防治化療所緻的延遲性噁心的完全控製率分彆為54.54％ (24/44)和32.50％ (13/40),有效率分彆為79.55％ (35/44)和57.50％ (23/40),差異均有統計學意義(P＜0.05);研究組和對照組防治化療所緻的延遲性嘔吐的完全控製率分彆為45.45％ (20/44)和22.50％ (9/40),有效率分彆為75.00％(33/44)和52.50％(21/40),差異均有統計學意義(P＜0.05).研究組和對照組治療後血漿胃動素較治療前明顯降低[(308.35±14.59) ng/L比(370.59±15.72) ng/L和(341.87±18.38) ng/L比(365.36±23.72) ng/L],血漿胃泌素較治療前明顯升高[(206.97±12.29) ng/L比(164.56±14.17) ng/L和(171.58±13.53) ng/L比(158.42±17.29)ng/L],差異有統計學意義(P＜0.05),且兩組治療後比較差異有統計學意義(P＜0.05).兩組藥物不良反應髮生率比較差異無統計學意義(P＞0.05).結論 託烷司瓊聯閤舒必利能比常規使用託烷司瓊穫得更好的止吐效果.
목적 탐토탁완사경연합서필리치료순박방안화료소치악심、구토적료효화안전성,진일보탐토대위동소급위비소적영향.방법 장84례접수순박방안치료병출현악심、구토적환자안수궤배렬표법분위연구조(44례)화대조조(40례),량조환자도급여염산탁완사경정맥추주,연구조동시구복서필리.관찰량충치료방안적료효、불량반응급대위동소화위비소적영향.결과 연구조화대조조방치화료소치적급성악심적완전공제솔분별위59.09％ (26/44)화37.50％ (15/40),유효솔분별위90.91％(30/44)화72.50％ (29/40),차이균유통계학의의(P＜0.05);연구조화대조조방치화료소치적급성구토적완전공제솔분별위61.36％(27/44)화37.50％ (15/40),유효솔분별위88.64％(39/44)화67.50％(27/40),차이균유통계학의의(P＜0.05);연구조화대조조방치화료소치적연지성악심적완전공제솔분별위54.54％ (24/44)화32.50％ (13/40),유효솔분별위79.55％ (35/44)화57.50％ (23/40),차이균유통계학의의(P＜0.05);연구조화대조조방치화료소치적연지성구토적완전공제솔분별위45.45％ (20/44)화22.50％ (9/40),유효솔분별위75.00％(33/44)화52.50％(21/40),차이균유통계학의의(P＜0.05).연구조화대조조치료후혈장위동소교치료전명현강저[(308.35±14.59) ng/L비(370.59±15.72) ng/L화(341.87±18.38) ng/L비(365.36±23.72) ng/L],혈장위비소교치료전명현승고[(206.97±12.29) ng/L비(164.56±14.17) ng/L화(171.58±13.53) ng/L비(158.42±17.29)ng/L],차이유통계학의의(P＜0.05),차량조치료후비교차이유통계학의의(P＜0.05).량조약물불량반응발생솔비교차이무통계학의의(P＞0.05).결론 탁완사경연합서필리능비상규사용탁완사경획득경호적지토효과.
Objective To investigate the efficacy and safety of tropisetron combined with sulpiride in treatment of chemotherapy-induced cisplatin program nausea and vomiting,so as to explore the effect to motilin and gastrin.Methods A total of 84 patients with chemotherapy-induced cisplatin program nausea and vomiting were divided into study group (44 cases) and control group (40 cases) by random digits table method,the patients in two groups were given tropisetron hydrochloride intravenous injection,and the study group was added sulpiride.The efficacy and side effects and effect to motilin and gastrin were observed.Results The fully control rate and efficient rate in acute nausea was 59.09％ (26/44),37.50％ (15/40),and 90.91％ (30/44),72.50％ (29/40) in study group and control group,and there was significant difference (P ＜ 0.05).The fully control rate and efficient rate in acute vomiting was 61.36 ％ (27/44),37.50％ (15/40),and 88.64％ (39/44),67.50％ (27/40) in study group and control group,and there was significant difference (P ＜0.05).The fully control rate and efficient rate in delayed nausea was 54.54％ (24/44),32.50％ (13/40),and 79.55％ (35/44),57.50％ (23/40) in study group and control group,and there was significant difference (P ＜ 0.05).The fully control rate and efficient rate in delayed vomiting was 45.45 ％ (20/44),22.50％ (9/40),and 75.00％ (33/44),52.50％ (21/40) in study group and control group,and there was significant difference (P＜ 0.05).The plasma motilin after treatment was lower than that before treatment in study group and control group[(308.35 ± 14.59) ng/L vs.(370.59 ± 15.72) ng/L and(341.87 ± 18.38) ng/L vs.(365.36 ± 23.72) ng/L],gastrin was higher than that before treatment in study group and control group [(206.97 ± 12.29) ng/L vs.(164.56 ± 14.17) ng/L and (171.58 ± 13.53) ng/L vs.(158.42 ± 17.29) ng/L],and there was significant difference (P ＜ 0.05).There was significant difference in the plasma motilin and gastrin after treatment between two groups (P ＜ 0.05).There was no significant difference in the occurrence of adverse drug reactions between two groups (P ＞ 0.05).Conclusion Tropisetron combined with sulpiride than the routine use of tropisetron can obtain the better the antiemetic effect.
